A Follow-up Physician Survey to Evaluate Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe

Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe: A Follow-up Physician Survey

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04067583

Enrollment

454

Registered

2019-08-26

Start date

2019-10-08

Completion date

2020-04-23

Last updated

2021-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ophthalmology, Macular Degeneration

Brief summary

With this follow up physician survey researcher want to collect the same data from all participants of the study using a highly structured questionnaire. The questionnaire will gather information related to physician characteristics and experience with Aflibercept, as well as assess physicians' knowledge and understanding of storage and preparation, proper injection technique, and the risks associated with Aflibercept injection into the eye (intravitreal injection). Analysis will be done using descriptive statistics.

Interventions

OTHERPhysician questionnaire

This is a one-time cross-sectional survey of physicians, conducted electronically; there are no in person visits

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Has signed informed consent * Is a licensed and practicing ophthalmologist * Has prescribed and/or administered aflibercept to at least one patient in the past 6 months

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame
Percentage of physicians responding correctly to each individual knowledge question	Up to 1 year

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026